Published in Clin Cancer Res on March 15, 2006
Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy. Clin Cancer Res (2013) 2.00
Pharmacogenomics of gemcitabine: can genetic studies lead to tailor-made therapy? Br J Cancer (2007) 1.61
Pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 1.55
Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood (2008) 1.46
Single nucleotide polymorphisms of gemcitabine metabolic genes and pancreatic cancer survival and drug toxicity. Clin Cancer Res (2009) 1.25
Pharmacogenetic variants in the DPYD, TYMS, CDA and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br J Cancer (2013) 1.19
Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. Cancer (2010) 1.05
Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabine. Blood (2011) 1.02
Pharmacokinetics and pharmacogenetics of Gemcitabine as a mainstay in adult and pediatric oncology: an EORTC-PAMM perspective. Cancer Chemother Pharmacol (2016) 0.98
Genetic factors influencing cytarabine therapy. Pharmacogenomics (2009) 0.97
The clinically relevant pharmacogenomic changes in acute myelogenous leukemia. Pharmacogenomics (2012) 0.94
Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. Br J Haematol (2008) 0.94
Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice. Cancer Chemother Pharmacol (2010) 0.89
Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism. Oncologist (2011) 0.89
Genotyping panel for assessing response to cancer chemotherapy. BMC Med Genomics (2008) 0.88
Gemcitabine metabolic pathway genetic polymorphisms and response in patients with non-small cell lung cancer. Pharmacogenet Genomics (2012) 0.83
Gemcitabine Cytotoxicity: Interaction of Efflux and Deamination. J Drug Metab Toxicol (2011) 0.80
Genetic effects and modifiers of radiotherapy and chemotherapy on survival in pancreatic cancer. Pancreas (2011) 0.80
Human cytidine deaminase: a biochemical characterization of its naturally occurring variants. Int J Biol Macromol (2013) 0.80
Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030). Br J Cancer (2013) 0.78
Gemcitabine-(C4-amide)-[anti-HER2/neu] Anti-Neoplastic Cytotoxicity in Dual Combination with Mebendazole against Chemotherapeutic-Resistant Mammary Adenocarcinoma. J Clin Exp Oncol (2015) 0.77
Synthesis of Gemcitabine-(C4-amide)-[anti-HER2/neu] Utilizing a UV-Photoactivated Gemcitabine Intermediate: Cytotoxic Anti-Neoplastic Activity against Chemotherapeutic-Resistant Mammary Adenocarcinoma SKBr-3. J Cancer Ther (2012) 0.77
Cytidine deaminase polymorphisms and worse treatment response in normal karyotype AML. J Hum Genet (2015) 0.76
Letter to the editor: pharmacokinetics of gemcitabine in non-small-cell lung cancer patients: impact of the 79A>C cytidine deaminase polymorphism. Eur J Clin Pharmacol (2010) 0.76
H-gemcitabine: a new gemcitabine prodrug for treating cancer. Bioconjug Chem (2012) 0.76
Contribution of FKBP5 genetic variation to gemcitabine treatment and survival in pancreatic adenocarcinoma. PLoS One (2013) 0.76
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-HER2/neu] in Combination with Griseofulvin against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3). Med Chem (Los Angeles) (2013) 0.75
Gemcitabine-(5'-phosphoramidate)-[anti-IGF-1R]: molecular design, synthetic organic chemistry reactions, and antineoplastic cytotoxic potency in populations of pulmonary adenocarcinoma (A549). Chem Biol Drug Des (2016) 0.75
Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. J Cancer Res Ther Oncol (2014) 0.75
Role of Genetic Polymorphisms of Deoxycytidine Kinase and Cytidine Deaminase to Predict Risk of Death in Children with Acute Myeloid Leukemia. Biomed Res Int (2015) 0.75
Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies. Pharmacogenomics J (2016) 0.75
Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol (2005) 6.90
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA (2009) 5.05
The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat (2006) 4.35
Genomics and drug response. N Engl J Med (2011) 4.35
Metabolomics: a global biochemical approach to drug response and disease. Annu Rev Pharmacol Toxicol (2008) 3.48
Genome-wide associations and functional genomic studies of musculoskeletal adverse events in women receiving aromatase inhibitors. J Clin Oncol (2010) 3.02
The Rat Genome Database (RGD): developments towards a phenome database. Nucleic Acids Res (2005) 2.77
Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J Hepatol (2010) 2.33
A phase II trial of Xeloda and oxaliplatin (XELOX) neo-adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para-aortic lymph node metastasis. Cancer Chemother Pharmacol (2014) 2.26
Targeted delivery of gemcitabine to pancreatic adenocarcinoma using cetuximab as a targeting agent. Cancer Res (2008) 2.20
3' tag digital gene expression profiling of human brain and universal reference RNA using Illumina Genome Analyzer. BMC Genomics (2009) 2.12
Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol (2009) 2.06
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood (2012) 1.96
Bayesian dose-finding in phase I/II clinical trials using toxicity and efficacy odds ratios. Biometrics (2006) 1.95
Curcumin (diferuloylmethane) alters the expression profiles of microRNAs in human pancreatic cancer cells. Mol Cancer Ther (2008) 1.92
Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing. Blood (2010) 1.90
Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol (2012) 1.81
Glutathione S-transferase T1 and M1: gene sequence variation and functional genomics. Clin Cancer Res (2007) 1.75
Gemcitabine and arabinosylcytosin pharmacogenomics: genome-wide association and drug response biomarkers. PLoS One (2009) 1.75
Mocetinostat for relapsed classical Hodgkin's lymphoma: an open-label, single-arm, phase 2 trial. Lancet Oncol (2011) 1.75
Human arsenic methyltransferase (AS3MT) pharmacogenetics: gene resequencing and functional genomics studies. J Biol Chem (2006) 1.74
Human aromatase: gene resequencing and functional genomics. Cancer Res (2005) 1.71
A proposed nomenclature system for the cytosolic sulfotransferase (SULT) superfamily. Pharmacogenetics (2004) 1.65
Synchronous selection of homing peptides for multiple tissues by in vivo phage display. FASEB J (2006) 1.63
Phase 0 clinical chemoprevention trial of the Akt inhibitor SR13668. Cancer Prev Res (Phila) (2011) 1.57
Identification of gene mutations in autosomal dominant polycystic kidney disease through targeted resequencing. J Am Soc Nephrol (2012) 1.57
Phase I and pharmacokinetic study of two different schedules of oxaliplatin, irinotecan, Fluorouracil, and leucovorin in patients with solid tumors. J Clin Oncol (2003) 1.54
Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. BMC Med Genomics (2014) 1.53
A phase I trial of twice-weekly 17-allylamino-demethoxy-geldanamycin in patients with advanced cancer. Clin Cancer Res (2006) 1.51
Monitoring late-onset toxicities in phase I trials using predicted risks. Biostatistics (2007) 1.48
Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). J Clin Oncol (2006) 1.43
Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report. J Clin Oncol (2010) 1.42
Pharmacogenomics: candidate gene identification, functional validation and mechanisms. Hum Mol Genet (2008) 1.41
Solitary fibrous tumor of the pleura: an analysis of 13 cases. World J Surg (2008) 1.41
Primer on medical genomics part I: History of genetics and sequencing of the human genome. Mayo Clin Proc (2002) 1.39
Functional genetic polymorphisms in the aromatase gene CYP19 vary the response of breast cancer patients to neoadjuvant therapy with aromatase inhibitors. Cancer Res (2010) 1.37
Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet (2006) 1.37
The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 1.37
Genetic alterations associated with progression from pancreatic intraepithelial neoplasia to invasive pancreatic tumor. Gastroenterology (2013) 1.34
Merging pharmacometabolomics with pharmacogenomics using '1000 Genomes' single-nucleotide polymorphism imputation: selective serotonin reuptake inhibitor response pharmacogenomics. Pharmacogenet Genomics (2012) 1.34
Role of the glutathione metabolic pathway in lung cancer treatment and prognosis: a review. J Clin Oncol (2006) 1.33
Retrograde type A aortic dissection after endovascular stent graft placement for treatment of type B dissection. Circulation (2009) 1.33
CYP2D6 metabolism and patient outcome in the Austrian Breast and Colorectal Cancer Study Group trial (ABCSG) 8. Clin Cancer Res (2012) 1.33
Toxicology and pharmacokinetics of 1-methyl-d-tryptophan: absence of toxicity due to saturating absorption. Food Chem Toxicol (2007) 1.32
Dose--schedule finding in phase I/II clinical trials using a Bayesian isotonic transformation. Stat Med (2008) 1.32
Fabrication and characterization of polycrystalline WO3 nanofibers and their application for ammonia sensing. J Phys Chem B (2006) 1.32
Prognostic significance of the IASLC/ATS/ERS classification in Chinese patients-A single institution retrospective study of 292 lung adenocarcinoma. J Surg Oncol (2012) 1.30
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Identification of side population cells in human hepatocellular carcinoma cell lines with stepwise metastatic potentials. J Cancer Res Clin Oncol (2008) 1.28
A comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches. Breast Cancer Res Treat (2006) 1.25
Multi-platform analysis of microRNA expression measurements in RNA from fresh frozen and FFPE tissues. PLoS One (2013) 1.24
Thiopurine S-methyltransferase pharmacogenetics: variant allele functional and comparative genomics. Pharmacogenet Genomics (2005) 1.23
Advantages of endoscopic submucosal dissection with needle-knife over endoscopic mucosal resection for small rectal carcinoid tumors: a retrospective study. Surg Endosc (2010) 1.23
Implementing individualized medicine into the medical practice. Am J Med Genet C Semin Med Genet (2014) 1.21
Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol (2010) 1.21
Human thiopurine S-methyltransferase pharmacogenetics: variant allozyme misfolding and aggresome formation. Proc Natl Acad Sci U S A (2005) 1.20
Alpha1-antitrypsin and neutrophil elastase imbalance and lung cancer risk. Chest (2005) 1.20
Glutathione S-transferase omega 1 and omega 2 pharmacogenomics. Drug Metab Dispos (2006) 1.17
Contribution of diffusion-weighted magnetic resonance imaging in the characterization of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver. J Comput Assist Tomogr (2010) 1.16
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol (2009) 1.16
Phase II study of oral capsular 4-hydroxyphenylretinamide (4-HPR/fenretinide) in pediatric patients with refractory or recurrent neuroblastoma: a report from the Children's Oncology Group. Clin Cancer Res (2011) 1.16
Mate pair sequencing of whole-genome-amplified DNA following laser capture microdissection of prostate cancer. DNA Res (2012) 1.15
Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer. Cancer Res (2010) 1.14
Primer on medical genomics. Part XII: Pharmacogenomics--general principles with cancer as a model. Mayo Clin Proc (2004) 1.14
Cytokeratin 10 and cytokeratin 19: predictive markers for poor prognosis in hepatocellular carcinoma patients after curative resection. Clin Cancer Res (2008) 1.13
Decreased selenium-binding protein 1 enhances glutathione peroxidase 1 activity and downregulates HIF-1α to promote hepatocellular carcinoma invasiveness. Clin Cancer Res (2012) 1.13
Aromatase inhibitors, estrogens and musculoskeletal pain: estrogen-dependent T-cell leukemia 1A (TCL1A) gene-mediated regulation of cytokine expression. Breast Cancer Res (2012) 1.13
CT and MRI diagnosis of hepatic epithelioid hemangioendothelioma. Hepatobiliary Pancreat Dis Int (2010) 1.12
Hepatic angiomyolipoma: various appearances on two-phase contrast scanning of spiral CT. Eur J Radiol (2002) 1.12
Selective estrogen receptor modulators and pharmacogenomic variation in ZNF423 regulation of BRCA1 expression: individualized breast cancer prevention. Cancer Discov (2013) 1.12